首页 > 最新文献

Cancer Control最新文献

英文 中文
Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma. 切除修复交叉互补组 1 对鼻咽癌循环肿瘤细胞的预后意义
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241251562
Ting Liu, Yuanqing Li, Junmei Song, Bo Li, Rensheng Wang, Tingting Huang, Yutao Qin

Background: Liquid biopsy, including the detection of circulating tumor cells (CTCs), has emerged as a promising tool for cancer diagnosis and monitoring. However, the prognostic value of CTCs in nasopharyngeal carcinoma (NPC) remains unclear due to the lack of phenotypic characterization. The expression of Excision Repair Cross-Complementation Group 1 (ERCC1) and CTCs epithelial-mesenchymal transition (EMT) have been associated with treatment efficacy. In this study, we aimed to evaluate the prognostic significance of ERCC1 expression on CTCs and their EMT subtypes before treatment in NPC.

Methods: We retrospectively analyzed 108 newly diagnosed locally advanced NPC patients who underwent CanPatrol™ CTC testing between November 2018 and November 2021. CTCs were counted and classified into epithelial, epithelial-mesenchymal hybrid, and mesenchymal subtypes. ERCC1 expression was divided into negative and positive groups. Clinical features and survival outcomes were analyzed.

Results: The positive rate of CTCs was 92.6% (100/108), with an ERCC1 positivity rate of 74% (74/100). Further analysis of the subtypes showed that positive ERCC1 on mesenchymal CTCs was associated with a later N stage (P = .01). Positive ERCC1 expression was associated with poor overall survival (OS; P = .039) and disease-free survival (DFS; P = .035). Further analysis of subtypes showed that the positive ERCC1 on mesenchymal-type CTCs was associated with poor OS (P = .012) and metastasis-free survival (MFS; P = .001).

Conclusion: Our findings suggest that ERCC1 expression on CTCs may serve as a new prognostic marker for NPC patients. Evaluating CTCs subtypes may become an auxiliary tool for personalized and precise treatment.

背景:包括检测循环肿瘤细胞(CTCs)在内的液体活检已成为一种很有前途的癌症诊断和监测工具。然而,由于缺乏表型特征描述,鼻咽癌(NPC)CTC 的预后价值仍不明确。切除修复交叉互补组 1(ERCC1)和 CTCs 上皮-间质转化(EMT)的表达与治疗效果有关。本研究旨在评估ERCC1在鼻咽癌治疗前对CTC及其EMT亚型表达的预后意义:我们回顾性分析了2018年11月至2021年11月期间接受CanPatrol™ CTC检测的108例新诊断的局部晚期NPC患者。我们对 CTC 进行了计数,并将其分为上皮亚型、上皮-间质混合亚型和间质亚型。ERCC1表达分为阴性组和阳性组。对临床特征和生存结果进行了分析:CTC阳性率为92.6%(100/108),其中ERCC1阳性率为74%(74/100)。对亚型的进一步分析表明,间质型 CTC 的 ERCC1 阳性与 N 分期较晚有关(P = .01)。ERCC1 阳性表达与总生存期(OS;P = 039)和无病生存期(DFS;P = 035)差有关。对亚型的进一步分析表明,间质型CTC上的ERCC1阳性与OS(P = .012)和无转移生存期(MFS;P = .001)差有关:我们的研究结果表明,CTCs上的ERCC1表达可作为鼻咽癌患者新的预后标志物。评估 CTCs 亚型可能成为个性化精准治疗的辅助工具。
{"title":"Prognostic Significance of Excision Repair Cross-Complementation Group 1 on Circulating Tumor Cells for Nasopharyngeal Carcinoma.","authors":"Ting Liu, Yuanqing Li, Junmei Song, Bo Li, Rensheng Wang, Tingting Huang, Yutao Qin","doi":"10.1177/10732748241251562","DOIUrl":"10.1177/10732748241251562","url":null,"abstract":"<p><strong>Background: </strong>Liquid biopsy, including the detection of circulating tumor cells (CTCs), has emerged as a promising tool for cancer diagnosis and monitoring. However, the prognostic value of CTCs in nasopharyngeal carcinoma (NPC) remains unclear due to the lack of phenotypic characterization. The expression of Excision Repair Cross-Complementation Group 1 (ERCC1) and CTCs epithelial-mesenchymal transition (EMT) have been associated with treatment efficacy. In this study, we aimed to evaluate the prognostic significance of ERCC1 expression on CTCs and their EMT subtypes before treatment in NPC.</p><p><strong>Methods: </strong>We retrospectively analyzed 108 newly diagnosed locally advanced NPC patients who underwent CanPatrol™ CTC testing between November 2018 and November 2021. CTCs were counted and classified into epithelial, epithelial-mesenchymal hybrid, and mesenchymal subtypes. ERCC1 expression was divided into negative and positive groups. Clinical features and survival outcomes were analyzed.</p><p><strong>Results: </strong>The positive rate of CTCs was 92.6% (100/108), with an ERCC1 positivity rate of 74% (74/100). Further analysis of the subtypes showed that positive ERCC1 on mesenchymal CTCs was associated with a later N stage (<i>P</i> = .01). Positive ERCC1 expression was associated with poor overall survival (OS; <i>P</i> = .039) and disease-free survival (DFS; <i>P</i> = .035). Further analysis of subtypes showed that the positive ERCC1 on mesenchymal-type CTCs was associated with poor OS (<i>P</i> = .012) and metastasis-free survival (MFS; <i>P</i> = .001).</p><p><strong>Conclusion: </strong>Our findings suggest that ERCC1 expression on CTCs may serve as a new prognostic marker for NPC patients. Evaluating CTCs subtypes may become an auxiliary tool for personalized and precise treatment.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241251562"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11080756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140877752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disparities in Mammography Screening: Analyzing Barriers to Access Using Individual Patient Perspectives and the Health Belief Model. 乳腺放射摄影筛查中的差异:利用患者个人观点和健康信念模型分析获得检查的障碍。
IF 2.6 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241248367
Eline M van den Broek-Altenburg, Abimbola A Leslie, Jamie S Benson, Kristen K DeStigter

Objective: The objective of our study is to explore Nepali women's beliefs about access to mammography screening, and motivations to get screened or not. This work was intended to be hypothesis generating for subsequent quantitative analysis and to inform policy and decision-making to improve access.

Methods: We conducted structured qualitative interviews among nine Nepali women in the Northeast of the United States receiving care at a local community health center and among nine white women receiving mammography care at a large academic medical center in the Northeast. We analyzed the transcripts using a mixed deductive (content analysis) and inductive (grounded theory) approach. Deductive codes were generated from the Health Belief Model which states that a person's belief in the real threat of a disease with their belief in the effectiveness of the recommended health service or behavior or action will predict the likelihood the person will adopt the behavior. We compared and contrasted qualitative results from both groups.

Results: We found that eligible Nepali women who had not received mammography screening had no knowledge of its availability and its importance. Primary care physicians emerged as a critical link in addressing this disparity: trust was found to be high among Nepali women with their established primary care provider.

Conclusion: The findings of this study suggest that the role of primary care practitioners in conversations around the importance and eligibility for mammography screening is of critical importance, especially for underserved groups with limited health knowledge of screening opportunities and potential health benefits. Follow-up research should focus on primary care practices.

研究目的我们的研究旨在探讨尼泊尔妇女对乳房 X 射线照相筛查的看法,以及是否接受筛查的动机。这项工作旨在为后续的定量分析提出假设,并为改善筛查机会的政策和决策提供信息:我们对在美国东北部一家社区医疗中心接受治疗的九名尼泊尔妇女和在东北部一家大型学术医疗中心接受乳腺 X 射线照相术治疗的九名白人妇女进行了结构化定性访谈。我们采用混合演绎法(内容分析法)和归纳法(基础理论)对访谈记录进行了分析。演绎代码来自健康信念模型,该模型指出,一个人对疾病真实威胁的信念以及对推荐的健康服务或行为或行动有效性的信念将预测该人采取该行为的可能性。我们对两组的定性结果进行了比较和对比:结果:我们发现,没有接受过乳房 X 射线照相筛查的合格尼泊尔妇女不了解乳房 X 射线照相筛查的可用性及其重要性。初级保健医生是解决这一差异的关键环节:我们发现尼泊尔妇女对其固定的初级保健提供者非常信任:这项研究的结果表明,初级保健医生在围绕乳腺 X 射线照相筛查的重要性和资格的对话中扮演着至关重要的角色,尤其是对于对筛查机会和潜在健康益处的健康知识有限的服务不足群体而言。后续研究应侧重于初级保健实践。
{"title":"Disparities in Mammography Screening: Analyzing Barriers to Access Using Individual Patient Perspectives and the Health Belief Model.","authors":"Eline M van den Broek-Altenburg, Abimbola A Leslie, Jamie S Benson, Kristen K DeStigter","doi":"10.1177/10732748241248367","DOIUrl":"10.1177/10732748241248367","url":null,"abstract":"<p><strong>Objective: </strong>The objective of our study is to explore Nepali women's beliefs about access to mammography screening, and motivations to get screened or not. This work was intended to be hypothesis generating for subsequent quantitative analysis and to inform policy and decision-making to improve access.</p><p><strong>Methods: </strong>We conducted structured qualitative interviews among nine Nepali women in the Northeast of the United States receiving care at a local community health center and among nine white women receiving mammography care at a large academic medical center in the Northeast. We analyzed the transcripts using a mixed deductive (content analysis) and inductive (grounded theory) approach. Deductive codes were generated from the Health Belief Model which states that a person's belief in the real threat of a disease with their belief in the effectiveness of the recommended health service or behavior or action will predict the likelihood the person will adopt the behavior. We compared and contrasted qualitative results from both groups.</p><p><strong>Results: </strong>We found that eligible Nepali women who had not received mammography screening had no knowledge of its availability and its importance. Primary care physicians emerged as a critical link in addressing this disparity: trust was found to be high among Nepali women with their established primary care provider.</p><p><strong>Conclusion: </strong>The findings of this study suggest that the role of primary care practitioners in conversations around the importance and eligibility for mammography screening is of critical importance, especially for underserved groups with limited health knowledge of screening opportunities and potential health benefits. Follow-up research should focus on primary care practices.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241248367"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11100395/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140946304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effect of Microvascular Invasion on Hepatocellular Carcinoma With Portal Vein Tumor Thrombus After Hepatectomy: A Retrospective Study. 微血管侵犯对肝切除术后伴有门静脉瘤栓的肝细胞癌的影响:一项回顾性研究
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241265257
Qingyi Xu, Liqin Lan, Jinhua Zeng, Jianxing Zeng

Background: There is no report resolving whether microvascular invasion (MVI) affects the prognosis of hepatectomy for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). The present study aimed to investigate the effect of MVI on HCC with PVTT after hepatectomy.

Methods: 362 HCC patients with PVTT were included in this retrospective study. Diagnostic criteria of PVTT in HCC patients were based on typical preoperative radiological features on imaging studies. The log-rank test was utilized to differentiate overall survival (OS) and recurrence-free survival (RFS) rates between the two groups. Univariate and multivariate Cox proportional hazard regression was utilized to detect independent factors.

Results: PVTT without MVI accounted for 12.2% (n = 44). PVTT without MVI groups was significantly superior to PVTT with MVI groups in OS (the median survival = 27.1 months vs 13.7 months) and RFS (the median survival = 6.4 months vs 4.1 months). The 1-, 3-, and 5-year OS rates (65.5%, 36.8%, 21.7% vs 53.5%, 18.7%, 10.1%, P = .014) and RFS rates (47.0%, 29.7%, 19.2% vs 28.7%, 12.2%, 6.9%, P = .005) were significant different between two groups. Multivariate analysis showed that MVI was an independent risk factor for OS (hazard ratio (HR) = 1.482; P-value = .045) and RFS (HR = 1.601; P-value = .009).

Conclusions: MVI was an independent prognostic factor closely linked to tumor recurrence and poorer clinical outcomes for HCC patients with PVTT after hepatectomy. MVI should be included in current PVTT systems to supplement to the PVTT type.

背景:微血管侵犯(MVI)是否会影响伴有门静脉肿瘤血栓(PVTT)的肝细胞癌(HCC)患者肝切除术的预后,目前尚无相关报道。本研究旨在探讨 MVI 对肝切除术后伴有 PVTT 的 HCC 的影响。HCC患者PVTT的诊断标准基于术前影像学检查的典型放射学特征。采用对数秩检验来区分两组患者的总生存率(OS)和无复发生存率(RFS)。利用单变量和多变量考克斯比例危险回归检测独立因素:结果:无 MVI 的 PVTT 占 12.2%(n = 44)。在OS(中位生存期=27.1个月 vs 13.7个月)和RFS(中位生存期=6.4个月 vs 4.1个月)方面,无MVI的PVTT组明显优于有MVI的PVTT组。两组间的 1、3 和 5 年 OS 率(65.5%、36.8%、21.7% vs 53.5%、18.7%、10.1%,P = .014)和 RFS 率(47.0%、29.7%、19.2% vs 28.7%、12.2%、6.9%,P = .005)差异显著。多变量分析显示,MVI是OS(危险比(HR)=1.482;P值=0.045)和RFS(HR=1.601;P值=0.009)的独立危险因素:结论:MVI是一个独立的预后因素,与肝切除术后PVTT的HCC患者的肿瘤复发和较差的临床预后密切相关。MVI应纳入目前的PVTT系统,作为PVTT类型的补充。
{"title":"The Effect of Microvascular Invasion on Hepatocellular Carcinoma With Portal Vein Tumor Thrombus After Hepatectomy: A Retrospective Study.","authors":"Qingyi Xu, Liqin Lan, Jinhua Zeng, Jianxing Zeng","doi":"10.1177/10732748241265257","DOIUrl":"10.1177/10732748241265257","url":null,"abstract":"<p><strong>Background: </strong>There is no report resolving whether microvascular invasion (MVI) affects the prognosis of hepatectomy for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). The present study aimed to investigate the effect of MVI on HCC with PVTT after hepatectomy.</p><p><strong>Methods: </strong>362 HCC patients with PVTT were included in this retrospective study. Diagnostic criteria of PVTT in HCC patients were based on typical preoperative radiological features on imaging studies. The log-rank test was utilized to differentiate overall survival (OS) and recurrence-free survival (RFS) rates between the two groups. Univariate and multivariate Cox proportional hazard regression was utilized to detect independent factors.</p><p><strong>Results: </strong>PVTT without MVI accounted for 12.2% (n = 44). PVTT without MVI groups was significantly superior to PVTT with MVI groups in OS (the median survival = 27.1 months vs 13.7 months) and RFS (the median survival = 6.4 months vs 4.1 months). The 1-, 3-, and 5-year OS rates (65.5%, 36.8%, 21.7% vs 53.5%, 18.7%, 10.1%, <i>P</i> = .014) and RFS rates (47.0%, 29.7%, 19.2% vs 28.7%, 12.2%, 6.9%, <i>P</i> = .005) were significant different between two groups. Multivariate analysis showed that MVI was an independent risk factor for OS (hazard ratio (HR) = 1.482; <i>P</i>-value = .045) and RFS (HR = 1.601; <i>P</i>-value = .009).</p><p><strong>Conclusions: </strong>MVI was an independent prognostic factor closely linked to tumor recurrence and poorer clinical outcomes for HCC patients with PVTT after hepatectomy. MVI should be included in current PVTT systems to supplement to the PVTT type.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241265257"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11403670/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of High Body Mass Index in Early Life With the Development of Colorectal Cancer. 早年体重指数高与结肠直肠癌发病的关系
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241270582
Nian Wu, Yangyang Chen, Guosheng Li

Significance: This study on the relationship between early life high BMI and the development of CRC reveals the role of high BMI during childhood and adolescence in the occurrence and progression of CRC. It suggests the importance of restoring normal weight or reducing weight in individuals with high BMI early in life for the prevention of colorectal cancer.

意义重大:这项关于生命早期高体重指数与 CRC 发展之间关系的研究揭示了儿童和青少年时期的高体重指数在 CRC 的发生和发展中的作用。研究表明,恢复正常体重或减轻高体重指数人群的体重对预防结直肠癌非常重要。
{"title":"Association of High Body Mass Index in Early Life With the Development of Colorectal Cancer.","authors":"Nian Wu, Yangyang Chen, Guosheng Li","doi":"10.1177/10732748241270582","DOIUrl":"10.1177/10732748241270582","url":null,"abstract":"<p><strong>Significance: </strong>This study on the relationship between early life high BMI and the development of CRC reveals the role of high BMI during childhood and adolescence in the occurrence and progression of CRC. It suggests the importance of restoring normal weight or reducing weight in individuals with high BMI early in life for the prevention of colorectal cancer.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241270582"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11307362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141898731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Research Protocol for a Phase II Single-Arm Clinical Trial Assessing the Feasibility and Efficacy of Neoadjuvant Anastrozole in Patients With Luminal Breast Cancer and Low Proliferative Index: The ANNE Trial. 评估新辅助阿那曲唑治疗增殖指数低的腔隙型乳腺癌患者的可行性和有效性的 II 期单臂临床试验研究方案:ANNE 试验。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241272463
Carlos Eduardo Paiva, Alinne Tatiane Faria Silva, Izabella da Silva Oliveira, Vitor Souza Guimarães, Domício Carvalho Lacerda, Gustavo Ramos Teixeira, Anapaula Hidemi Uema Watanabe, Nilton Onari, Bianca Sakamoto Ribeiro Paiva, Idam de Oliveira-Junior, Marcia Maria Chiquitelli Marques, Yara Cristina de Paiva Maia

Introduction: Neoadjuvant endocrine therapy (NET) is recommended for the treatment of invasive breast cancer (BC), particularly luminal subtypes, in locally advanced stages. Previous randomized studies have demonstrated the benefits of aromatase inhibitors in this context. However, NET is typically reserved for elderly or frail patients who may not tolerate neoadjuvant chemotherapy. Identifying non-responsive patients early and extending treatment for responsive ones would be ideal, yet optimal strategies are awaited.

Aims: This non-randomized phase 2 clinical trial aims to assess NET feasibility and efficacy in postmenopausal stage II and III luminal BC patients, identifying predictive therapeutic response biomarkers. Efficacy will be gauged by patients with Ki67 ≤ 10% after 4 weeks and Preoperative Endocrine Prognostic Index (PEPI) scores 0 post-surgery. Study feasibility will be determined by participation acceptance rate (recruitment rate ≥50%) and inclusion rate (>2 patients/month).

Methods: Postmenopausal women with luminal, HER2-tumors in stages II and III undergo neoadjuvant anastrozole treatment, evaluating continuing NET or receiving chemotherapy through early Ki67 analysis after 2 to 4 weeks. The study assesses NET extension for up to 10 months, using serial follow-ups with standardized breast ultrasound and clinical criteria-based NET suspension. Clinical and pathological responses will be measured overall and in the luminal tumor A subgroup. Toxicity, health-related quality of life, and circulating biomarkers predicting early NET response will also be evaluated.

导言:新辅助内分泌疗法(NET)被推荐用于治疗浸润性乳腺癌(BC),尤其是局部晚期的管腔亚型。之前的随机研究已经证明了芳香化酶抑制剂在这方面的优势。然而,NET 通常只用于年老或体弱的患者,这些患者可能无法耐受新辅助化疗。目的:这项非随机的二期临床试验旨在评估NET对绝经后II期和III期腔性BC患者的可行性和疗效,并确定预测治疗反应的生物标志物。疗效将通过患者术后4周Ki67≤10%和术前内分泌预后指数(PEPI)评分为0来衡量。研究的可行性将通过参与接受率(招募率≥50%)和纳入率(>2 名患者/月)来确定:方法:患有管腔型 HER2 肿瘤 II 期和 III 期的绝经后妇女接受新辅助阿那曲唑治疗,通过 2 至 4 周后的早期 Ki67 分析评估是否继续接受 NET 或化疗。该研究通过标准化乳腺超声波和基于临床标准的NET悬浮液进行连续随访,评估NET的延续时间长达10个月。临床和病理反应将在总体和管腔肿瘤 A 亚组中进行测量。还将评估毒性、与健康相关的生活质量以及预测早期NET反应的循环生物标志物。
{"title":"A Research Protocol for a Phase II Single-Arm Clinical Trial Assessing the Feasibility and Efficacy of Neoadjuvant Anastrozole in Patients With Luminal Breast Cancer and Low Proliferative Index: The ANNE Trial.","authors":"Carlos Eduardo Paiva, Alinne Tatiane Faria Silva, Izabella da Silva Oliveira, Vitor Souza Guimarães, Domício Carvalho Lacerda, Gustavo Ramos Teixeira, Anapaula Hidemi Uema Watanabe, Nilton Onari, Bianca Sakamoto Ribeiro Paiva, Idam de Oliveira-Junior, Marcia Maria Chiquitelli Marques, Yara Cristina de Paiva Maia","doi":"10.1177/10732748241272463","DOIUrl":"10.1177/10732748241272463","url":null,"abstract":"<p><strong>Introduction: </strong>Neoadjuvant endocrine therapy (NET) is recommended for the treatment of invasive breast cancer (BC), particularly luminal subtypes, in locally advanced stages. Previous randomized studies have demonstrated the benefits of aromatase inhibitors in this context. However, NET is typically reserved for elderly or frail patients who may not tolerate neoadjuvant chemotherapy. Identifying non-responsive patients early and extending treatment for responsive ones would be ideal, yet optimal strategies are awaited.</p><p><strong>Aims: </strong>This non-randomized phase 2 clinical trial aims to assess NET feasibility and efficacy in postmenopausal stage II and III luminal BC patients, identifying predictive therapeutic response biomarkers. Efficacy will be gauged by patients with Ki67 ≤ 10% after 4 weeks and Preoperative Endocrine Prognostic Index (PEPI) scores 0 post-surgery. Study feasibility will be determined by participation acceptance rate (recruitment rate ≥50%) and inclusion rate (>2 patients/month).</p><p><strong>Methods: </strong>Postmenopausal women with luminal, HER2-tumors in stages II and III undergo neoadjuvant anastrozole treatment, evaluating continuing NET or receiving chemotherapy through early Ki67 analysis after 2 to 4 weeks. The study assesses NET extension for up to 10 months, using serial follow-ups with standardized breast ultrasound and clinical criteria-based NET suspension. Clinical and pathological responses will be measured overall and in the luminal tumor A subgroup. Toxicity, health-related quality of life, and circulating biomarkers predicting early NET response will also be evaluated.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241272463"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141976990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding and Addressing Prostate Cancer Disparities in Diagnosis, Treatment, and Outcomes Among Black Men. 了解并解决黑人男性在前列腺癌诊断、治疗和结果方面的差异。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241275389
Anastasia Murphy, Cherell C Cottrell-Daniels, Shivanshu Awasthi, Esther Katende, Jong Y Park, Justin Denis, B Lee Green, Kosj Yamoah

Despite advances in screening, diagnosis, and treatment for prostate cancer (PCa), Black men tend to be diagnosed at younger ages, have higher mortality rates, and are at increased risk of recurrence or metastasis compared to their White counterparts. PCa disparities among Black men are caused by a complex interaction of social, behavioral, and biological factors across the public policy, community, organizational, interpersonal, and individual levels. Key contributing factors include mistrust in the health care system, poor communication between patients and providers, low awareness of screening guidelines, and high medical costs. These disparities are further exacerbated by the low representation of Black men in clinical trials, which limits access to high-quality cancer care and generalizability for PCa treatments. In this narrative review of the existing literature, we examined the epidemiology and identified contributing factors, and propose multi-level strategies to address and mitigate disparities among Black men with PCa.

尽管在前列腺癌(PCa)的筛查、诊断和治疗方面取得了进步,但与白人男性相比,黑人男性被诊断出前列腺癌的年龄往往更小,死亡率更高,复发或转移的风险也更大。黑人男性中 PCa 的差异是由公共政策、社区、组织、人际和个人层面的社会、行为和生物因素的复杂相互作用造成的。主要因素包括对医疗保健系统的不信任、患者与医疗服务提供者之间沟通不畅、对筛查指南的认识不足以及高昂的医疗费用。由于黑人男性在临床试验中的代表性较低,这些差异进一步加剧,从而限制了获得高质量癌症治疗的机会和 PCa 治疗的推广性。在这篇对现有文献的叙述性综述中,我们研究了流行病学并确定了诱发因素,同时提出了多层次的策略来解决和减少黑人男性 PCa 患者之间的差异。
{"title":"Understanding and Addressing Prostate Cancer Disparities in Diagnosis, Treatment, and Outcomes Among Black Men.","authors":"Anastasia Murphy, Cherell C Cottrell-Daniels, Shivanshu Awasthi, Esther Katende, Jong Y Park, Justin Denis, B Lee Green, Kosj Yamoah","doi":"10.1177/10732748241275389","DOIUrl":"10.1177/10732748241275389","url":null,"abstract":"<p><p>Despite advances in screening, diagnosis, and treatment for prostate cancer (PCa), Black men tend to be diagnosed at younger ages, have higher mortality rates, and are at increased risk of recurrence or metastasis compared to their White counterparts. PCa disparities among Black men are caused by a complex interaction of social, behavioral, and biological factors across the public policy, community, organizational, interpersonal, and individual levels. Key contributing factors include mistrust in the health care system, poor communication between patients and providers, low awareness of screening guidelines, and high medical costs. These disparities are further exacerbated by the low representation of Black men in clinical trials, which limits access to high-quality cancer care and generalizability for PCa treatments. In this narrative review of the existing literature, we examined the epidemiology and identified contributing factors, and propose multi-level strategies to address and mitigate disparities among Black men with PCa.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241275389"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141989295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
KRAS, NRAS and BRAF Mutational Profile of Colorectal Cancer in a Series of Moroccan Patients. 一系列摩洛哥患者的结直肠癌 KRAS、NRAS 和 BRAF 基因突变谱。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241262179
Sara El Zaitouni, Abdelilah Laraqui, Meriem Ghaouti, Asmae Benzekri, Fouad Kettani, Tahar Bajjou, Yassine Sekhsokh, Soukaina Benmokhtar, Meryem Jafari, Walid Baba, Mohamed Oukabli, Hicham El Annaz, Rachid Abi, Mohamed Rida Tagajdid, Safae El Kochri, Idriss Amine Lahlou, Rabii Ameziane El Hassani, Khalid Ennibi

Objectives: The present study aimed to evaluate the frequencies of KRAS, NRAS, and BRAF mutations and their possible associations with clinicopathological features in 249 Moroccan patients with colorectal cancer (CRC).

Methods: A retrospective investigation of a cohort of formalin-fixed paraffin-embedded tissues of 249 patients with CRC was screened for KRAS/NRAS/BRAF mutations using Idylla™ technology and pyrosequencing.

Results: KRAS, NRAS, and BRAF mutations were revealed in 46.6% (116/249), 5.6% (14/249), and 2.4% (6/249) of patients. KRAS exon 2 mutations were identified in 87.9% of patients (102/116). KRAS G12D and G12 C were the most frequent, at 32.8% and 12.93%, respectively. Among the patients with KRAS exon 2 wild-type (wt), 27.6% (32/116) harbored additional KRAS mutations. Concurrent KRAS mutations were identified in 9.5% (11/116); including six in codon 146 (A146P/T/V), three in codon 61 (Q61H/L/R), one in codon 12 (G12 A and Q61H), and one in codon 13 (G13D and Q61 L). Among the NRAS exon 2 wt patients, 64.3% (9/14) harbored additional NRAS mutations. Concurrent NRAS mutations were identified in 28.6% (4/14) of NRAS-mutant patients. Since 3.2% wt KRAS were identified with NRAS mutations, concomitant KRAS and NRAS mutations were identified in 2.4% (6/249) of patients. KRAS mutations were higher in the >50-year-old age-group (P = .031), and the tumor location was revealed to be significantly associated with KRAS mutations (P = .028) predominantly in left colon (27.5%) and colon (42.2%) locations. NRAS mutations were most prevalent in the left colon (42.8%) and in well-differentiated tumors (64.2%).

Conclusion: Detection of KRAS mutations, particularly the G12 C subtype, may be significant for patients with CRC and has possible therapeutic implications. However, rare KRAS concomitant mutations in CRC patients suggest that each individual may present distinct therapeutic responses. KRAS testing alongside the identification of other affected genes in the same patient will make the treatments even more personalized by contributing more accurately to the clinical decision process. Overall, early diagnosis using novel molecular techniques may improve the management of CRC by providing the most efficient therapies for Moroccan patients.

研究目的本研究旨在评估 249 名摩洛哥结直肠癌(CRC)患者中 KRAS、NRAS 和 BRAF 突变的频率及其与临床病理特征的可能关联:采用 Idylla™ 技术和热测序技术对 249 例 CRC 患者的福尔马林固定石蜡包埋组织进行了 KRAS/NRAS/BRAF 突变的回顾性调查:结果:46.6%(116/249)、5.6%(14/249)和 2.4%(6/249)的患者发现了 KRAS、NRAS 和 BRAF 突变。87.9%的患者(102/116)发现了 KRAS 第 2 外显子突变。KRAS G12D和G12 C是最常见的突变,分别占32.8%和12.93%。在KRAS外显子2野生型(wt)患者中,27.6%(32/116)的患者携带额外的KRAS突变。9.5%的患者(11/116)发现了并发的KRAS突变,其中6例发生在146密码子(A146P/T/V),3例发生在61密码子(Q61H/L/R),1例发生在12密码子(G12 A和Q61H),1例发生在13密码子(G13D和Q61 L)。在 NRAS 外显子 2 wt 患者中,64.3%(9/14)的患者携带额外的 NRAS 突变。28.6%(4/14)的 NRAS 突变患者同时发现了 NRAS 突变。由于 3.2% 的 KRAS 基因突变患者同时发现了 NRAS 基因突变,2.4% 的患者(6/249)同时发现了 KRAS 和 NRAS 基因突变。KRAS突变在50岁以上年龄组中发生率较高(P = .031),肿瘤位置与KRAS突变显著相关(P = .028),主要发生在左结肠(27.5%)和结肠(42.2%)。NRAS突变在左侧结肠(42.8%)和分化良好的肿瘤(64.2%)中最为常见:结论:KRAS突变的检测,尤其是G12 C亚型的检测,可能对CRC患者有重要意义,并有可能产生治疗效果。然而,CRC 患者中罕见的 KRAS 并发突变表明,每个人可能会有不同的治疗反应。在对同一患者进行 KRAS 检测的同时,对其他受影响基因的鉴定也将有助于临床决策过程,从而使治疗更加个性化。总之,利用新型分子技术进行早期诊断可为摩洛哥患者提供最有效的疗法,从而改善对 CRC 的管理。
{"title":"<i>KRAS</i>, <i>NRAS</i> and <i>BRAF</i> Mutational Profile of Colorectal Cancer in a Series of Moroccan Patients.","authors":"Sara El Zaitouni, Abdelilah Laraqui, Meriem Ghaouti, Asmae Benzekri, Fouad Kettani, Tahar Bajjou, Yassine Sekhsokh, Soukaina Benmokhtar, Meryem Jafari, Walid Baba, Mohamed Oukabli, Hicham El Annaz, Rachid Abi, Mohamed Rida Tagajdid, Safae El Kochri, Idriss Amine Lahlou, Rabii Ameziane El Hassani, Khalid Ennibi","doi":"10.1177/10732748241262179","DOIUrl":"10.1177/10732748241262179","url":null,"abstract":"<p><strong>Objectives: </strong>The present study aimed to evaluate the frequencies of <i>KRAS</i>, <i>NRAS,</i> and <i>BRAF</i> mutations and their possible associations with clinicopathological features in 249 Moroccan patients with colorectal cancer (CRC).</p><p><strong>Methods: </strong>A retrospective investigation of a cohort of formalin-fixed paraffin-embedded tissues of 249 patients with CRC was screened for <i>KRAS</i>/<i>NRAS</i>/<i>BRAF</i> mutations using Idylla™ technology and pyrosequencing.</p><p><strong>Results: </strong><i>KRAS</i>, <i>NRAS,</i> and <i>BRAF</i> mutations were revealed in 46.6% (116/249), 5.6% (14/249), and 2.4% (6/249) of patients. <i>KRAS</i> exon 2 mutations were identified in 87.9% of patients (102/116). <i>KRAS</i> G12D and G12 C were the most frequent, at 32.8% and 12.93%, respectively. Among the patients with <i>KRAS</i> exon 2 wild-type (wt), 27.6% (32/116) harbored additional <i>KRAS</i> mutations. Concurrent <i>KRAS</i> mutations were identified in 9.5% (11/116); including six in codon 146 (A146P/T/V), three in codon 61 (Q61H/L/R), one in codon 12 (G12 A and Q61H), and one in codon 13 (G13D and Q61 L). Among the <i>NRAS</i> exon 2 wt patients, 64.3% (9/14) harbored additional <i>NRAS</i> mutations. Concurrent <i>NRAS</i> mutations were identified in 28.6% (4/14) of <i>NRAS</i>-mutant patients. Since 3.2% wt <i>KRAS</i> were identified with <i>NRAS</i> mutations, concomitant <i>KRAS</i> and <i>NRAS</i> mutations were identified in 2.4% (6/249) of patients. <i>KRAS</i> mutations were higher in the >50-year-old age-group (<i>P</i> = .031), and the tumor location was revealed to be significantly associated with <i>KRAS</i> mutations (<i>P</i> = .028) predominantly in left colon (27.5%) and colon (42.2%) locations. <i>NRAS</i> mutations were most prevalent in the left colon (42.8%) and in well-differentiated tumors (64.2%).</p><p><strong>Conclusion: </strong>Detection of <i>KRAS</i> mutations, particularly the G12 C subtype, may be significant for patients with CRC and has possible therapeutic implications. However, rare <i>KRAS</i> concomitant mutations in CRC patients suggest that each individual may present distinct therapeutic responses. <i>KRAS</i> testing alongside the identification of other affected genes in the same patient will make the treatments even more personalized by contributing more accurately to the clinical decision process. Overall, early diagnosis using novel molecular techniques may improve the management of CRC by providing the most efficient therapies for Moroccan patients.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241262179"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141321904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary Rehabilitation Exercises Effectively Improve Chronic Cough After Surgery for Non-small Cell Lung Cancer. 肺康复训练能有效改善非小细胞肺癌术后的慢性咳嗽。
IF 2.6 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241255824
Nanzhi Luo, Fuqiang Dai, Xintian Wang, Binbin Hu, Lin Zhang, Kejia Zhao

Introduction: Cough is a major complication after lung cancer surgery, potentially impacting lung function and quality of life. However, effective treatments for managing long-term persistent postoperative cough remain elusive. In this study, we investigated the potential of a pulmonary rehabilitation training program to effectively address this issue.

Methods: Between January 2019 and December 2022, a retrospective review was conducted on patients with non-small cell lung cancer (NSCLC) who underwent lobectomy and lymph node dissection via video-assisted thoracoscopic surgery (VATS) at Daping hospital. Based on their postoperative rehabilitation methods, the patients were categorized into 2 groups: the traditional rehabilitation group and the pulmonary rehabilitation group. All patients underwent assessment using the Leicester cough questionnaire (LCQ) on the third postoperative day. Additionally, at the 6-month follow-up, patients' LCQ scores and lung function were re-evaluated to assess the long-term effects of the pulmonary rehabilitation training programs.

Results: Among the 276 patients meeting the inclusion criteria, 195 (70.7%) were in the traditional rehabilitation group, while 81 (29.3%) participated in the pulmonary rehabilitation group. The pulmonary rehabilitation group showed a significantly lower incidence of cough on the third postoperative day (16.0% vs 29.7%, P = .018) and higher LCQ scores in the somatic dimension (5.09 ± .81 vs 4.15 ± 1.22, P = .007) as well as in the total score (16.44 ± 2.86 vs 15.11 ± 2.51, P = .018, whereas there were no significant differences in psychiatric and sociological dimensions. At the 6-month follow-up, the pulmonary rehabilitation group continued to have a lower cough incidence (3.7% vs 12.8%, P = .022) and higher LCQ scores across all dimensions: somatic (6.19 ± .11 vs 5.75 ± 1.20, P = .035), mental (6.37 ± 1.19 vs 5.85 ± 1.22, P = .002), sociological (6.76 ± 1.22 vs 5.62 ± 1.08, P < .001), and total (18.22 ± 2.37 vs 16.21 ± 2.53, P < .001). Additionally, lung function parameters including FVC, FVC%, FEV1, FEV1%, MVV, MVV%, DLCO SB, and DLCO% were all significantly higher in the pulmonary rehabilitation group compared to the traditional group.

Conclusion: Pulmonary rehabilitation exercises significantly reduced the incidence of postoperative cough and improved cough-related quality of life in patients undergoing lobectomy, with sustained benefits observed at the 6-month follow-up. Additionally, these exercises demonstrated superior lung function outcomes compared to traditional rehabilitation methods.

简介:咳嗽是肺癌手术后的主要并发症:咳嗽是肺癌手术后的主要并发症,可能会影响肺功能和生活质量。然而,治疗术后长期持续咳嗽的有效方法仍未出现。在这项研究中,我们调查了肺康复训练计划有效解决这一问题的潜力:2019年1月至2022年12月期间,我们对大坪医院通过视频辅助胸腔镜手术(VATS)进行肺叶切除和淋巴结清扫的非小细胞肺癌(NSCLC)患者进行了回顾性研究。根据术后康复方法,患者被分为两组:传统康复组和肺部康复组。所有患者均在术后第三天接受了莱斯特咳嗽问卷(LCQ)评估。此外,在6个月的随访中,重新评估了患者的LCQ评分和肺功能,以评估肺康复训练项目的长期效果:在符合纳入标准的 276 名患者中,195 人(70.7%)属于传统康复组,81 人(29.3%)属于肺康复组。肺康复组在术后第三天的咳嗽发生率明显降低(16.0% vs 29.7%,P = .018),躯体维度的 LCQ 得分(5.09 ± .81 vs 4.15 ± 1.22,P = .007)和总分(16.44 ± 2.86 vs 15.11 ± 2.51,P = .018)均高于传统康复组,而精神和社会维度则无明显差异。在 6 个月的随访中,肺康复组的咳嗽发生率仍然较低(3.7% vs 12.8%,P = .022),LCQ 各方面的得分也较高:躯体方面(6.19 ± .11 vs 5.75 ± 1.20,P = .035)、精神(6.37 ± 1.19 vs 5.85 ± 1.22,P = .002)、社会学(6.76 ± 1.22 vs 5.62 ± 1.08,P < .001)和总分(18.22 ± 2.37 vs 16.21 ± 2.53,P < .001)。此外,肺康复组的肺功能参数,包括 FVC、FVC%、FEV1、FEV1%、MVV、MVV%、DLCO SB 和 DLCO% 均显著高于传统组:结论:肺康复锻炼能明显降低肺叶切除术患者术后咳嗽的发生率,并改善与咳嗽相关的生活质量,在6个月的随访中观察到持续的益处。此外,与传统康复方法相比,肺功能康复训练效果更佳。
{"title":"Pulmonary Rehabilitation Exercises Effectively Improve Chronic Cough After Surgery for Non-small Cell Lung Cancer.","authors":"Nanzhi Luo, Fuqiang Dai, Xintian Wang, Binbin Hu, Lin Zhang, Kejia Zhao","doi":"10.1177/10732748241255824","DOIUrl":"10.1177/10732748241255824","url":null,"abstract":"<p><strong>Introduction: </strong>Cough is a major complication after lung cancer surgery, potentially impacting lung function and quality of life. However, effective treatments for managing long-term persistent postoperative cough remain elusive. In this study, we investigated the potential of a pulmonary rehabilitation training program to effectively address this issue.</p><p><strong>Methods: </strong>Between January 2019 and December 2022, a retrospective review was conducted on patients with non-small cell lung cancer (NSCLC) who underwent lobectomy and lymph node dissection via video-assisted thoracoscopic surgery (VATS) at Daping hospital. Based on their postoperative rehabilitation methods, the patients were categorized into 2 groups: the traditional rehabilitation group and the pulmonary rehabilitation group. All patients underwent assessment using the Leicester cough questionnaire (LCQ) on the third postoperative day. Additionally, at the 6-month follow-up, patients' LCQ scores and lung function were re-evaluated to assess the long-term effects of the pulmonary rehabilitation training programs.</p><p><strong>Results: </strong>Among the 276 patients meeting the inclusion criteria, 195 (70.7%) were in the traditional rehabilitation group, while 81 (29.3%) participated in the pulmonary rehabilitation group. The pulmonary rehabilitation group showed a significantly lower incidence of cough on the third postoperative day (16.0% vs 29.7%, <i>P</i> = .018) and higher LCQ scores in the somatic dimension (5.09 ± .81 vs 4.15 ± 1.22, <i>P</i> = .007) as well as in the total score (16.44 ± 2.86 vs 15.11 ± 2.51, <i>P</i> = .018, whereas there were no significant differences in psychiatric and sociological dimensions. At the 6-month follow-up, the pulmonary rehabilitation group continued to have a lower cough incidence (3.7% vs 12.8%, <i>P</i> = .022) and higher LCQ scores across all dimensions: somatic (6.19 ± .11 vs 5.75 ± 1.20, <i>P</i> = .035), mental (6.37 ± 1.19 vs 5.85 ± 1.22, <i>P</i> = .002), sociological (6.76 ± 1.22 vs 5.62 ± 1.08, <i>P</i> < .001), and total (18.22 ± 2.37 vs 16.21 ± 2.53, <i>P</i> < .001). Additionally, lung function parameters including FVC, FVC%, FEV1, FEV1%, MVV, MVV%, DLCO SB, and DLCO% were all significantly higher in the pulmonary rehabilitation group compared to the traditional group.</p><p><strong>Conclusion: </strong>Pulmonary rehabilitation exercises significantly reduced the incidence of postoperative cough and improved cough-related quality of life in patients undergoing lobectomy, with sustained benefits observed at the 6-month follow-up. Additionally, these exercises demonstrated superior lung function outcomes compared to traditional rehabilitation methods.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241255824"},"PeriodicalIF":2.6,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141066243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer Worry and Fatalism at the Intersection of Race and Hearing Status. 种族与听力状况交织下的癌症担忧与宿命论。
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241291615
Emmanuel C Perrodin-Njoku, Sowmya R Rao, Christopher J Moreland, Regina M Wang, Poorna Kushalnagar

Introduction: The deaf and hard of hearing (DHH) community experiences lower cancer screening rates than the general population. Cancer worry and fatalism can influence cancer screening, along with race, and the interaction of intrinsic factors with DHH health behavior needs to be investigated.

Objectives: The study examines the association of the intersection of race and hearing status with cancer worry and fatalism.

Methods: This study analyzed cross-sectional survey data from NCI HINTS-ASL (for DHH adults) and NCI HINTS (for hearing adults). Multivariable logistic regression models were used to assess (i) the association of race-hearing status intersection with cancer worry and fatalism, as well as (ii) the relationship between hearing status and outcomes within each race.

Results: The study found that the overall interaction between race and hearing status was significantly associated with both high cancer worry and fatalism, with African American (AA)/Black and Asian/Other having higher odds of worry [1.17 (0.83, 1.64); 1.19 (0.85, 1.66), respectively] and other groups having lower worry than White hearing (P < 0.0001), and all deaf having less concern about cancer fatalism (P < 0.0001). Within each racial group, White DHH respondents had lower odds of cancer worry [aOR (95% CI): 0.72 (0.58, 0.91); P < 0.01] and fatalism [0.55 (0.46, 0.67); P < 0.0001] compared to White hearing respondents, while DHH AA/Black [1.89 (1.06, 3.37); P = 0.03], Asian/Other [2.39 (1.06, 3.37); P = 0.03], and Hispanic [1.95 (1.18, 3.22); P < 0.01] respondents had significantly higher odds of cancer worry and lower odds of cancer fatalism [Black: 0.50 (0.23, 1.09); P = 0.07; Asian/Other: [0.68 (0.42, 1.09); P = 0.10]; Hispanic: [0.69 (0.40, 1.17)]; P = 0.16] compared to their hearing counterparts.

Conclusion: DHH individuals have different odds of experiencing cancer worry and fatalism compared to their hearing counterparts. Inclusion of individuals with sensory disabilities in a larger cancer study sample enriches the diversity of perspectives, ensuring that the findings reflect a broader range of experiences and needs. More research into contributory factors in the signing DHH population is needed.

导言:聋人和重听人(DHH)群体的癌症筛查率低于普通人群。癌症担忧和宿命论与种族一样会影响癌症筛查,因此需要研究内在因素与 DHH 健康行为之间的相互作用:本研究探讨了种族和听力状况与癌症担忧和宿命论之间的关联:本研究分析了NCI HINTS-ASL(针对DHH成人)和NCI HINTS(针对听力成人)的横断面调查数据。研究采用多变量逻辑回归模型来评估(i)种族-听力状况交叉与癌症担忧和宿命论的关系,以及(ii)听力状况与每个种族的结果之间的关系:研究发现,种族与听力状况之间的整体交互作用与高度癌症忧虑和宿命论有显著关联,其中非裔美国人(AA)/黑人和亚裔/其他群体的忧虑几率更高[分别为 1.17 (0.83, 1.64); 1.19 (0.85, 1.66)],其他群体的忧虑几率低于白人听力(P < 0.0001),所有聋人对癌症宿命论的忧虑较低(P < 0.0001)。在每个种族组中,与白人听力受访者相比,白人 DHH 受访者担心癌症的几率[aOR (95% CI):0.72 (0.58, 0.91);P < 0.01]和宿命论[0.55 (0.46, 0.67);P < 0.0001]更低,而 DHH AA/Black [1.89 (1.06, 3. 37);P = 0.03]更低。37); P = 0.03]、亚裔/其他族裔[2.39 (1.06, 3.37); P = 0.03]和西班牙裔[1.95 (1.18, 3.22); P < 0.01]受访者担心癌症的几率明显较高,而担心癌症死亡的几率较低[黑人:0.50 (0.23, 1.09); P = 0.07; 亚裔/其他族裔:[0.68 (0.42, 0.49); P = 0.0001]]:[0.68(0.42,1.09);P = 0.10];西班牙裔:[0.69(0.40,1.17)];P = 0.16]:结论:与听力正常的人相比,听力残疾的人有不同程度的癌症忧虑和宿命论。将感官残疾人士纳入更大规模的癌症研究样本中,可以丰富研究视角的多样性,确保研究结果能够反映更广泛的经验和需求。需要对手语残疾的 DHH 群体中的促成因素进行更多的研究。
{"title":"Cancer Worry and Fatalism at the Intersection of Race and Hearing Status.","authors":"Emmanuel C Perrodin-Njoku, Sowmya R Rao, Christopher J Moreland, Regina M Wang, Poorna Kushalnagar","doi":"10.1177/10732748241291615","DOIUrl":"10.1177/10732748241291615","url":null,"abstract":"<p><strong>Introduction: </strong>The deaf and hard of hearing (DHH) community experiences lower cancer screening rates than the general population. Cancer worry and fatalism can influence cancer screening, along with race, and the interaction of intrinsic factors with DHH health behavior needs to be investigated.</p><p><strong>Objectives: </strong>The study examines the association of the intersection of race and hearing status with cancer worry and fatalism.</p><p><strong>Methods: </strong>This study analyzed cross-sectional survey data from NCI HINTS-ASL (for DHH adults) and NCI HINTS (for hearing adults). Multivariable logistic regression models were used to assess (i) the association of race-hearing status intersection with cancer worry and fatalism, as well as (ii) the relationship between hearing status and outcomes within each race.</p><p><strong>Results: </strong>The study found that the overall interaction between race and hearing status was significantly associated with both high cancer worry and fatalism, with African American (AA)/Black and Asian/Other having higher odds of worry [1.17 (0.83, 1.64); 1.19 (0.85, 1.66), respectively] and other groups having lower worry than White hearing (<i>P</i> < 0.0001), and all deaf having less concern about cancer fatalism (<i>P</i> < 0.0001). Within each racial group, White DHH respondents had lower odds of cancer worry [aOR (95% CI): 0.72 (0.58, 0.91); <i>P</i> < 0.01] and fatalism [0.55 (0.46, 0.67); <i>P</i> < 0.0001] compared to White hearing respondents, while DHH AA/Black [1.89 (1.06, 3.37); <i>P</i> = 0.03], Asian/Other [2.39 (1.06, 3.37); <i>P</i> = 0.03], and Hispanic [1.95 (1.18, 3.22); <i>P</i> < 0.01] respondents had significantly higher odds of cancer worry and lower odds of cancer fatalism [Black: 0.50 (0.23, 1.09); <i>P</i> = 0.07; Asian/Other: [0.68 (0.42, 1.09); <i>P</i> = 0.10]; Hispanic: [0.69 (0.40, 1.17)]; <i>P</i> = 0.16] compared to their hearing counterparts.</p><p><strong>Conclusion: </strong>DHH individuals have different odds of experiencing cancer worry and fatalism compared to their hearing counterparts. Inclusion of individuals with sensory disabilities in a larger cancer study sample enriches the diversity of perspectives, ensuring that the findings reflect a broader range of experiences and needs. More research into contributory factors in the signing DHH population is needed.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241291615"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11475122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors Influencing Knowledge and Acceptance of Nonavalent Human Papillomavirus Vaccine Among University Population in Southern China: A Cross-Sectional Study. 影响华南地区高校人群对无价人乳头瘤病毒疫苗的认知和接受程度的因素:一项横断面研究
IF 2.5 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 DOI: 10.1177/10732748241293989
Peiwan Fang, Haiyan Zheng, Li Liu, Jie Pan, Mianjia Chen, Xiaolin Yu, Miao Chen, Weicheng Yuan

Background: Vaccine hesitancy among young Chinese remains a challenge, contributing to low vaccination rates for the nonavalent Human Papillomavirus (HPV) vaccine. This study evaluated the knowledge and acceptance of this vaccine among students at a southern Chinese university and identified factors influencing these outcomes.

Methods: This cross-sectional, anonymous questionnaire survey was conducted from April to November 2023 at a multi-campus university in southern China. The questionnaire was comprised of three sections: the first collected demographic data; the second evaluated students' knowledge of the nonavalent HPV vaccine on a scale from 0 to 15, with cut-off points at 5 and 10 delineating low, medium, and high knowledge levels, respectively; the third section assessed vaccine acceptance on a scale from 8 to 40, using scores above the 50th percentile as the benchmark for positive acceptance.

Results: Among the participants, 18% demonstrated low-level, 40.20% medium-level, and 41.70% high-level knowledge of the nonavalent HPV vaccine. Notably, 71.95% of respondents showed positive acceptance, whereas 28.05% expressed negative acceptance. Male students and those with lower economic conditions (monthly living expenses below 1000 RMB, P = 0.004; 1000-1499 RMB, P = 0.012) exhibited lower knowledge levels. As for acceptance, female students and those with higher monthly living expenses (1000-1499 RMB, P = 0.007; 1500-1999 RMB, P = 0.002; over 2000 RMB, P = 0.002) demonstrated greater vaccine acceptance. A positive correlation was noted between the level of knowledge and vaccine acceptance (rs = 0.256, P < 0.001).

Conclusions: Gender and economic status are significantly associated with nonavalent HPV vaccine knowledge and acceptance among university students. These findings highlight the potential impact of targeted educational initiatives, especially for economically disadvantaged male students, in enhancing vaccine uptake rates.

背景:中国年轻人对接种疫苗犹豫不决仍是一个挑战,这也是导致无价人乳头瘤病毒(HPV)疫苗接种率低的原因之一。本研究评估了中国南方一所大学的学生对该疫苗的了解和接受程度,并确定了影响这些结果的因素:这项横断面匿名问卷调查于 2023 年 4 月至 11 月在中国南方一所多校区大学进行。问卷由三部分组成:第一部分收集人口统计学数据;第二部分评估学生对无价HPV疫苗的了解程度,量表范围为0-15分,5分和10分的分界点分别代表低、中和高的了解程度;第三部分评估疫苗的接受程度,量表范围为8-40分,以高于第50百分位数的分数作为积极接受的基准:结果:在参与者中,18% 的人对无毒 HPV 疫苗的知识水平较低,40.20% 的人处于中等水平,41.70% 的人处于较高水平。值得注意的是,71.95%的受访者表示积极接受,28.05%的受访者表示消极接受。男生和经济条件较差者(月生活费低于 1000 元,P = 0.004;1000-1499 元,P = 0.012)的知识水平较低。在接受度方面,女生和月生活费较高的学生(1000-1499 元,P = 0.007;1500-1999 元,P = 0.002;2000 元以上,P = 0.002)对疫苗的接受度更高。知识水平与疫苗接受度之间呈正相关(rs = 0.256,P < 0.001):结论:性别和经济状况与大学生对无空洞 HPV 疫苗的了解和接受程度密切相关。结论:性别和经济状况与大学生对无病毒 HPV 疫苗的了解和接受程度有很大关系。这些发现凸显了有针对性的教育措施(尤其是针对经济状况不佳的男生)对提高疫苗接种率的潜在影响。
{"title":"Factors Influencing Knowledge and Acceptance of Nonavalent Human Papillomavirus Vaccine Among University Population in Southern China: A Cross-Sectional Study.","authors":"Peiwan Fang, Haiyan Zheng, Li Liu, Jie Pan, Mianjia Chen, Xiaolin Yu, Miao Chen, Weicheng Yuan","doi":"10.1177/10732748241293989","DOIUrl":"10.1177/10732748241293989","url":null,"abstract":"<p><strong>Background: </strong>Vaccine hesitancy among young Chinese remains a challenge, contributing to low vaccination rates for the nonavalent Human Papillomavirus (HPV) vaccine. This study evaluated the knowledge and acceptance of this vaccine among students at a southern Chinese university and identified factors influencing these outcomes.</p><p><strong>Methods: </strong>This cross-sectional, anonymous questionnaire survey was conducted from April to November 2023 at a multi-campus university in southern China. The questionnaire was comprised of three sections: the first collected demographic data; the second evaluated students' knowledge of the nonavalent HPV vaccine on a scale from 0 to 15, with cut-off points at 5 and 10 delineating low, medium, and high knowledge levels, respectively; the third section assessed vaccine acceptance on a scale from 8 to 40, using scores above the 50th percentile as the benchmark for positive acceptance.</p><p><strong>Results: </strong>Among the participants, 18% demonstrated low-level, 40.20% medium-level, and 41.70% high-level knowledge of the nonavalent HPV vaccine. Notably, 71.95% of respondents showed positive acceptance, whereas 28.05% expressed negative acceptance. Male students and those with lower economic conditions (monthly living expenses below 1000 RMB, <i>P</i> = 0.004; 1000-1499 RMB, <i>P</i> = 0.012) exhibited lower knowledge levels. As for acceptance, female students and those with higher monthly living expenses (1000-1499 RMB, <i>P</i> = 0.007; 1500-1999 RMB, <i>P</i> = 0.002; over 2000 RMB, <i>P</i> = 0.002) demonstrated greater vaccine acceptance. A positive correlation was noted between the level of knowledge and vaccine acceptance (r<sub>s</sub> = 0.256, <i>P</i> < 0.001).</p><p><strong>Conclusions: </strong>Gender and economic status are significantly associated with nonavalent HPV vaccine knowledge and acceptance among university students. These findings highlight the potential impact of targeted educational initiatives, especially for economically disadvantaged male students, in enhancing vaccine uptake rates.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"31 ","pages":"10732748241293989"},"PeriodicalIF":2.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528755/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Cancer Control
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1